Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer
- International Joint Cancer Institute, The Second Military Medical University, Shanghai 200433 (China)
- Department of Vascular Surgery, Changhai Hospital, The Second Military Medical University, Shanghai 200433 (China)
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032 (China)
- Department of Gastroenterology, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu (China)
Despite of the effectiveness of the anti-ErbB2 humanized antibody trastuzumab, trastuzumab resistance emerges as a major and common clinical problem. Thus, circumventing trastuzumab resistance has become an urgent need. Recently, Src inhibitor saracatinib has drawn great attention for its key role in trastuzumab response. As shown in our previous study, H2-18, an anti-ErbB2 antibody, could potently induce programmed cell death (PCD) in trastuzumab-resistant breast cancer cells. Here we combined H2-18 and a Src inhibitor, saracatinib, and studied the antitumor activity of this drug combination in trastuzumab-resistant breast cancer cell lines. The results showed that H2-18 and saracatinib could synergistically inhibit cell proliferation of BT-474, SKBR-3, HCC-1954 and HCC-1419 breast cancer cell lines in vitro. H2-18 plus saracatinib could also inhibit the HCC-1954 tumor growth more effectively in vivo than each drug alone. H2-18 plus saracatinib showed a significantly more potent PCD-inducing activity compared with either H2-18 or saracatinib alone. We conclude that enhanced PCD may contribute to the superior antitumor efficacy of this combination therapy. The combination of H2-18 and SRC inhibitor has the potential to be translated into clinic. - Highlights: • Anti-ErbB2 mAb H2-18 induces PCD in ErbB2-overexpresing breast cancer cells. • H2-18 plus saracatinib induce a greater PCD compared with either drug alone. • H2-18 and saracatinib synergistically inhibit in vitro cell proliferation of breast cancer cells. • H2-18 plus saracatinib exert a greater in vivo antitumor activity than either drug alone.
- OSTI ID:
- 22696658
- Journal Information:
- Biochemical and Biophysical Research Communications, Vol. 479, Issue 3; Other Information: Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth
A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma